Introduction

45
Approximately 200 million prescriptions are issued annually for children and young people in the UK 46 (Costello et al., 2004) . Previous studies have investigated medicines adherence in children, however 47 these have not explored potential barriers to adherence in the domiciliary setting. In this paper, 48 barriers are defined as obstacles that could result in non-adherence of medicines (e.g. forgetting, 49 refuse, hard to swallow, etc.). 50
There is a paucity of studies investigating barriers to medicines administration arising from oral 51 formulations (particularly those related to organoleptic and physical properties) in children with 52 chronic conditions. Those studies reported previously are limited to specific disease groups, e.g. . 59
The present study targets a large paediatric population suffering from different chronic conditions. 60
The palatability of paediatric medicines is one of the most important formulation factors with 61 potential to influence adherence to therapeutic regimens and outcomes (Salunke et al., 2011) . It has 62 been demonstrated that making medications more pleasing to the child can have a positive effect on 63 compliance (Winnick et al., 2005) . Refusal of a formulation was defined in the present study as, 64
'complete omission of a dose by intent on at least one occasion, including spitting the dose back out, 65 and/or closing the mouth' and medicine manipulation was defined as 'a medicine physically adapted 66 to facilitate medicines administration or for the purpose of giving a specific dose.' 67 Protocol -TIP (Marhefka et al., 2004) 
Qualitative Analysis
111
Themes were identified using a frame-work analysis approach to form a coding spine. Thematic 112 content analysis (Pope et al., 2000) was used to identify and group common themes,relating to 113 medicines administration. Qualitative data was analysed using NVivo 8 software (QSR International). 114
Statistical Analysis
115
Statistical analysis was conducted using generalised estimating equations to explore the relationship 116 between independent variables (e.g. child age, IMD score, formulation type) and dependent 117 variables with binary outcomes (Refusal or Manipulation). 118
Patient, participant and data on formulations were converted into categorical variables (see Tables 2  119   & 3) . 120
Data analysis was performed on an individual medicine level facilitating comparisons between 121 medicine specific variables (e.g. different medicine groups and formulations), which are not possible 122 at a patient level. In order to account possible non-independence of data owing to any response 123 correlation to medicines taken by an individual, univariable generalised estimating equations were 124 used. The univariable analysis did not control for potential relationships between independent 125 variables therefore multivariable analysis was also conducted using the combination of independent 126 variables found to be significant (p<0.05) for the dependent variables in the univariable model 127 (medicines refusal, medicines manipulations). This generated Odds Ratios, 95% confidence intervals 128 and associated p values. The data was analysed using SPSS version 20 software (IBM It should be noted that not all patients in clinics were prescribed medicines, therefore not all 148 patients were eligible for study inclusion. There was a scheduled approach to accessing patients at 149 these clinics on a rotating basis to ensure wide coverage of the target patient population. UHCW is a 150 teaching hospital with three age-banded paediatric wards. All have a wide range of paediatric 151 patients without specialism. Inpatients from all three paediatric wards at UHCW were included at 152 the recruitment phase to minimise the risk of missing eligible patients who were hospitalised during 153 the study period. The recruitment phase lasted 15 months from November 2010 to February 2012. 154
Inclusion criteria
155
The study included children (aged 0-<18 years) with chronic conditions and their parents or carers. 156
Age bandings were based on pre-school; school-age and adolescents to match cognitive function. 157
Patients were eligible for inclusion if they had been taking prescribed medication for a chronic 158 condition for at least one month prior to their outpatient appointment. 159
Results
160
A total of 280 participants consented to the study (Figure 1 ). Interviews were completed with 221 161 parents/carers and 57 young people (in the presence of a parent/carer (n=42), in the absence of a 162 parent/carer (n=15)). In total, (91%) 252/278 of the children included were prescribed at least one 163 oral formulation. The remaining 26 patients were not prescribed any oral formulations, only non-164 oral formulations. The data from these patients was analysed separately and is not included in the 165 subsequent analyses. 166 167
Participant demographics and medicines
168
The 252 children receiving oral formulations were categorised into three age groups: 0-4 years 169 (n=92), 5-11 years (n=93) and 12-18 years (n=67), see Table 1 for the frequency of oral formulation 170 types prescribed. 171 n represents the number of children in each age range (0-4, 5-11 and 12-18 years)
174
In total, 542 oral formulations were prescribed across the cohort (with the number of oral 175 formulations prescribed to each patient ranging from 1 to 8). formulations were administered via nasogastric or percutaneous endoscopic gastrostomy tubes and 184 medicine refusal was not permitted, therefore data is unavailable on these medications for 10 185 patients. The medicines refusal question was not delivered to a further 10 participants owing to time 186 constraints. Almost one third (71/232) of respondents reported medicines refusal on at least one 187 occasion; multivariable statistical analysis was conducted on this data set. The results are reported in 188 
191
The age of child at interview was found to be a significant predictor of refusal, with children aged 192 In total, 19% (94/499) of formulations were manipulated. Of these, the majority (93%, 87/94) were 208 reported to be manipulated 'always' (i.e. prior to every dose administration). 209
210
Of the medicine manipulations reported, 26% (24/94) were performed for the purpose of 211 administering a specific dose (e.g. one quarter of a tablet), whilst the majority of medicine 212 manipulations, 79% (74/94) were performed to facilitate medicines administration (e.g. mixed into 213 foodstuffs). Omeprazole soluble tablets, macrogol 3350 oral powder, co-trimoxazole tablets and 214 mercaptopurine tablets were most often manipulated (by at least 40% of users). For over three 215 quarters (78% 7/9) of children prescribed omeprazole soluble tablets, medicines manipulation was 216 reported. 217
The age of the child at the interview was found to be a significant predictor of the reporting of 218 medicines manipulation (p=0.005). Reports became progressively less likely with increasing age, with 219
Odds Ratios of 0.29 (95% CI: 0.13-0.67; p=0.004) in the 5-11 year age group, and 0.18 (95% CI: 0.06-220 0.59; p=0.005) in the 12-18 year age group, relative to patients in the 0-4 year group. 221
The type of formulation was also associated significantly with reporting of medicines manipulation 222 (p<0.001), with tablets and capsules (OR: 9.66; 95% CI: 3.48-26.87; p<0.001) and other formulations 223 (granules, powders, soluble tablets and melts) (OR: 23.97; 95% CI: 9.14-62.84; p<0.001) both more 224 likely to be manipulated than liquids. Manipulation was also found to be significantly more likely to 225 be reported where patients had problems with either the size (OR: 4.52; 95% CI: 1.37-14.90; 226 p=0.013) or the texture (OR: 3.15; 95% CI: 1.39-7.14; p=0.006) of the medicines. In cases where the 227 child had partial responsibility for the administration of a medicine, significantly lower rates of 228 manipulation were reported, relative to where the parent or guardian was solely responsible (OR: 229 0.28; 95% CI: 0.10-0.81; p=0.019). A similar effect was observed where the child was totally 230 responsible for medicines administration, although this was not statistically significant (OR: 0.22; 231 95% CI: 0.02-1.94; p=0.171). The results are reported in Table 3 . 232 
Taste
237
Taste was the most commonly reported barrier to medicines administration affecting 35% (188/542) 238 of all prescribed oral formulations, and associated with 64% (54/85) of formulations that were 239 refused. 240
Formulations with the highest incidence of taste issues were ranitidine liquid (82%; 9/11 children), 241 prednisolone soluble tablets (81%; 13/16 children) and trimethoprim liquid (75%; 6/8 children) of 242 total users. However, taste issues were reported for at least 50% of children prescribed other 243 common drugs (lactulose liquid, macrogol 3350 oral powder sachets, co-trimoxazole tablets, sodium 244 valproate liquid, levetiracetam liquid, penicillin liquid, ibuprofen liquid and prednisolone tablets). 245
See Figure 2 for reported taste problems. 246
Texture
247
Texture was reported to affect 8% (42/542) of all prescribed oral formulations, and was a significant 248 predictor of medicines refusal. Co-trimoxazole liquid (38%), omeprazole soluble tablets (33%) and 249 lactulose liquid (25%) were most commonly reported to have texture-related problems. Specific 250 medicines identified with textural issues included: lactulose which was described as "oily" and co-251 trimoxazole liquid described as "thick and gelatinous" 252
Volume or Quantity
253
Of the medicines prescribed, 5% (29/542) were reported to have "too large" a volume or "too many" 254 solid dosage units to be administered at one dosing interval. Volume or quantity were reported as 255 barriers to administration for 63% ( reported. Problems specifically related to the sizes of particular solid dosage forms were reported 265 for 68% (19/28) of these medicines, and aversion to, or difficulty swallowing solid dosage forms was 266 reported for the remaining 32% (9/28) of medicines. It should be noted that these patients were not 267 physically unable to swallow (i.e. not patients fitted with an NG or PEG tube). The majority (7/8= 268 88%) of patients prescribed co-trimoxazole tablets reported a problem with their large size or 269 difficulties swallowing them. These children were aged from 4 to 15 years. Although specific data on 270 brand of formulation was not collected from parents, the size of co-trimoxazole tablets (480mg) was 271 measured to be an average of 11mm (based on the average diameter of two different 272 manufacturers).This could be expected based on the large amount of active ingredient within the 273 formulation. In contrast, there were no problems reported with the size of levothyroxine tablets, 274 owing to their significantly lower dose (micrograms) and therefore a comparatively smaller tablet. 275
Colour/appearance and smell
276
An unfavourable colour (descriptions provided included "alarming", off-putting, and colourless) was 277 associated with 2% (11/542) of medicines prescribed. Two of eighteen children prescribed sodium 278 valproate liquid highlighted its "alarming colour" .. Similarly, one of nine patients prescribed 279 paracetamol liquid described its unappealing colour. 280
In addition, 2% (11/542) of medicines prescribed were identified as having "off-putting" smells. For 281 25% (2/8) of children prescribed trimethoprim liquid, an unfavourable smell was reported. 282
Discussion
283
This study has indicated that formulations prescribed to children with chronic conditions are not 284 meeting the needs of a significant number of patients based on self-report. Medicines refusal was 285 associated significantly with barriers to oral medicines administration: taste, texture, 286 quantity/volume (see Table 2 ). Palatability needs to be considered carefully by pharmaceutical 287 companies when designing new formulations and also by prescribers in order to optimise effective 288 prescribing, maximising adherence, therapeutic effects and reducing wastage with cost savings. 289
Other statistically significant factors associated with medicines refusal were child age at interview 290 and IMD 2010 score. Recent EMA guidance (EMA, 2013) states that age-appropriateness of 291 formulations needs to be prominent in pharmaceutical development and also when designing 292 prescribing protocols for prescribers. Further research is required to investigate the relationship 293 between socio-demographic factors and medicines refusal. 294
The formulations highlighted to be problematic are also often prescribed to treat patients with acute 295 conditions, e.g. soluble prednisolone tablets. Evaluation of the study data can inform changes in 296 prescribing practice, e.g. prescribing prednisolone tablets in preference to soluble prednisolone 297 tablets for children; even though intuitively soluble tablets are considered to be age-appropriate for 298 paediatric populations. This change has been implemented at UHCW and it is estimated that this will 299 generate a cost saving of £5000 per annum in the Paediatric Department (Personal Communication, 300
2012). 301
This study identified that almost one third (29%) of participants reported manipulating medicines. Table 4 below. 306 307 Limited evidence is available on the effects of mixing drugs with various foodstuffs. Prolonging the 309 contact time of a drug with a foodstuff is likely to increase the binding capability and therefore may 310 risk reducing drug bioavailability, thus affect therapeutic response. Additionally, if a drug-foodstuff 311 mixture is not consumed in its entirety, the desired dose will not be administered. 312
To minimise unnecessary medicines manipulation it is essential that prescribers consider age-313 appropriateness, type of formulation (in relation to ease of administration), swallowing problems 314 and patient capability to swallow tablets according to size and also acceptance of different textures. 315
These factors were associated significantly with manipulation of medicines (see Table 3 ). The lower 316 reported refusal of solid dosage forms compared to liquids (see Table 2 ) may be associated with the 317 adoption of ad hoc manipulation techniques, and supporting this, medicines manipulation was 318 significantly associated with administering solid dosage forms (see Table 3 ). 319
Future formulation work needs to be implemented to develop age-appropriate formulations that are 320 accepted by children and are also available in appropriate unit doses, ideally pre-measured, covering 321 child dosing ranges and also small enough to taper doses accurately. Dosage form technologies such 322 A limitation within the present study is the reporting of generic formulations as opposed to specific 343 products (e.g. brands and manufacturers). This results from the nature of this pragmatic study which 344 relies upon parent/carer/patient reports. Nonetheless, this is the first study to explore barriers to 345 oral medicines administration in children with a wide range of chronic conditions. Further research is 346 required to identify whether similarly, problems are encountered with non-oral medicines and in 347 paediatric populations outside of the UK. 348 A limitation of using a self-report tool is the risk of inaccurate reporting (Butz, 2006) . In this study, 349 one mother reported that medication had not been omitted, however the adolescent in her care 350 provided an opposing report. This finding reinforces the need for future studies to investigate parent 351 and teenager reports independently. In the present study, there was insufficient time and resources 352 for parents and young people to be interviewed independently and the study was designed to be 353 pragmatic, thus reflect a family environment. A study by Buchanan and co-workers (2012) found 354 significant similarity between independent reports of 'taste/cannot get it down' (p<0.001), 355 forgetting (p<0.001), and also refusing doses (p=0.01) amongst young people with HIV and their 356 carers. These findings suggest that reporting of such outcomes is fairly consistent between carers 357 and young people, however this is only one study, conducted in children with HIV. 358
The statistical results may have been subject to confounding by other factors that were not 359 considered in the analysis and should be interpreted in light of this. However, since a range of 360 variables were considered in the analysis and a multivariable statistical approach was used, 361 confounding factors have been accounted for as far as was possible. 362 
Conclusions
